Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Admin, Dems Face Challenge In Showing Voters What Reform Means For Them
As health reform proposals emerge from congressional committees, partisan fighting boils and the president wades into the debate with a series of televised addresses, news reports turn to an unanswered question. "What"s in it for me?" asks David Leonhardt, the New York Times business columnist. "On the subject of health care reform, most Americans probably don"t have a good answer to the question. And that, obviously, is a problem for the White House and for Democratic leaders in Congress," he writes.

PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A
This month"s Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma"s L-CsA, inhaled liposomal cyclosporine A. In May, PARI Pharma received Orphan Drug Designation from the Food and Drug Administration for L-CsA, delivered via an Investigational eFlow Nebulizer System, for the prevention and treatment of bronchiolitis obliterans, a devastating, incurable disease of the small airways affecting approximately 60,000 patients worldwide.
News of the day
RISPERDAL CONSTA (risperidone) Long-Acting Treatment May Improve Health Outcomes And Reduce Hospitalizations In Patients With Schizophrenia
Schizophrenia is one of the most disabling diseases, and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers and society. According to two new studies, the use of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment (RLAT) may improve clinical and functional outcomes and reduce rates of rehospitalization among patients with schizophrenia. Results of the studies were presented this week at a major medical meeting.
Sexual Health

Innovative Hand Dryer Pilot To Help Combat HCAIs, UK

An innovative hand dryer aimed at cutting the risk of healthcare associated infections (HCAIs) has been launched for NHS trusts and healthcare organisations by NHS Supply Chain. NHS Supply Chain is running a pilot contract across the country for Dyson Airblade™ - the only hand dryer certified by the leading public health and safety company, NSF International.* The Dyson Airblade™ is the fastest and most efficient hand dryer. It dries hands up to four times quicker than standard hand dryers by scraping water off hands with a jet of air travelling at 400 mph, and eliminates 99.9% of bacteria from the air used to dry hands with a HEPA filter. "This truly is an innovation," said Chris Graham, Senior Buyer at NHS Supply Chain. "Wet hands harbour up to 1000 times more bacteria than dry hands and in turn spread infection across healthcare sites. Patients and healthcare workers are able to dry their hands within ten seconds and at a fraction of the cost." When compared with standard hand drying methods, each Dyson Airblade™ hand dryer can save NHS trusts up to ÷£2,000 a year in operating costs. "The Airblade has been introduced on a trial basis in response to customer interest," said Chris. "It is a welcome addition to our range of products aimed at helping NHS customers combat the threat of HCAIs." NHS Supply Chain


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009